<DOC>
	<DOC>NCT03085810</DOC>
	<brief_summary>This is a prospective, multicenter, open-label, single-arm, phase 3b study which evaluates effectiveness and safety of ocrelizumab in participants with early stage RRMS. The study will consist of an open-label treatment period of 192 weeks and follow-up period of at least 48 weeks.</brief_summary>
	<brief_title>Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS)</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
	<criteria>Have a definite diagnosis of RRMS, as per the revised McDonald 2010 criteria Have a length of disease duration, from first documented clinical attack consistent with MS disease of less than or equal to (&lt;/=) 3 years Within the last 12 months one or more clinically reported relapse(s) or one or more signs of MRI activity EDSS of 0.0 to 3.5 inclusive, at screening An agreement to use an acceptable birth control method for women of childbearing potential, during the treatment period and for at least 6 months after the last dose of study drug Secondary progressive multiple sclerosis (SPMS) or history of primary progressive or progressive relapsing MS Inability to complete an MRI Known presence of other neurological disorders Exclusions Related to General Health: Pregnancy or lactation Any concomitant disease that may require chronic treatment with systemic corticosteroids or immunosuppressants during the course of the study History or currently active primary or secondary immunodeficiency Lack of peripheral venous access History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies Significant or uncontrolled somatic disease or any other significant disease that may preclude participant from participating in the study Congestive heart failure (New York Heart Association [NYHA] III or IV functional severity) Known active bacterial, viral, fungal, mycobacterial infection or other infection, (excluding fungal infection of nail beds) or any major episode of infection requiring hospitalization or treatment with intravenous (IV) antibiotics within 4 weeks prior to screening or oral antibiotics 2 weeks prior to screening History of malignancy, major opportunistic infections, alcohol or drug abuse, recurrent or chronic infection, and/or coagulation disorders Exclusions Related to Medications: Received any prior approved disease modifying treatment (DMT) with a label for MS, for example, interferons, glatiramer acetate, natalizumab, alemtuzumab, daclizumab, fingolimod, teiflunomide and dimethylfumarate Receipt of a vaccine within 6 weeks prior to the baseline visit Previous treatment with Bcell targeted therapies (i.e., rituximab, ocrelizumab, atacicept, belimumab, or ofatumumab) Any previous treatment with immunosuppressants/ immunomodulators/ antineoplastic therapies (cyclophosphamide, azathioprine, mycophenolate mofetil, cyclosporine, methotrexate, cladribine, mitoxantrone, laquinimod, total body irradiation, or bone marrow transplantation) Treatment with investigational DMT Treatment with fampridine/dalfamipridine unless on stable dose for &gt;/=30 days prior to screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>